PARP INHIBITORS AS FRONTLINE TREATMENT IN PATIENTS WITH OVARIAN CANCER.

Citation metadata

Author: Kevin Wright
Date: Mar. 2020
From: Oncology(Vol. 34, Issue 3)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 693 words
Lexile Measure: 1400L

Document controls

Main content

Article Preview :

The time has come for maintenance treatment with poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors to become the standard of care in the frontline setting for patients with ovarian cancer. This message, backed by recent data from clinical trials, was at the forefront of the Society of Gynecologic Oncology's 25 th Annual Winter Meeting held February 6-8 in Aspen, CO.

"The rationale is that we may be curing more patients," said Kathleen M. Moore, MD, the Jim and Christy Everest Endowed Chair in Cancer Research at the Stephenson Cancer Center in Oklahoma City during a presentation. "If patients are going to benefit from [a] PARP, they're going to benefit most early on. We just need to identify those patients a little bit more accurately." (1) Moore's assertion is supported by results from 3 clinical trials--PAOLA-1, PRIMA, and VELIA--that were first released at the European Society for Medical Oncology Congress 2019.

The phase III PAOLA-1 trial, which tested the combination of bevacizumab (Avastin) plus olaparib (Lynparza) as maintenance therapy, showed an increase in median...

Source Citation

Source Citation   

Gale Document Number: GALE|A677572332